Assessing the cost-effectiveness of withdrawing growth hormone treatment after mid-puberty in adolescents with idiopathic isolated growth hormone deficiency
Recruiting
- Conditions
- Growth hormone deficiency10021112
- Registration Number
- NL-OMON55366
- Lead Sponsor
- Erasmus MC
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- Not specified
- Target Recruitment
- 128
Inclusion Criteria
GH treated adolescents with partial idiopathic isolated GH deficiency (IIGHD)
GH peak at diagnosis >5 mU/L and <30 mU/L
mid-puberty (boys: Tanner stage G3 or G4, testicular volume > 12 ml and bone
age 13-16 years; girls: Tanner stage B3 or B4 and bone age 11-14 years)
GH peak of > 20 mU/L at retesting in mid-puberty
GH treatment for at least 3 years
Informed consent
Exclusion Criteria
Medical or psychologic disorder, or medication other than GH, that could
potentially influence growth
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method <p>Primary: adult height (AH) minus target height (TH) SDS. Secondary: adult<br /><br>height SDS, total pubertal growth (cm), and satisfaction with attained adult<br /><br>height. </p><br>
- Secondary Outcome Measures
Name Time Method <p>Secondary: adult height SDS, total pubertal growth (cm), and satisfaction with<br /><br>attained adult height. </p><br>
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie idiopathic isolated growth hormone deficiency in adolescents?
How does growth hormone withdrawal after mid-puberty compare to continuous treatment in long-term outcomes for patients with idiopathic isolated growth hormone deficiency?
Are there specific biomarkers that predict response to growth hormone treatment withdrawal in adolescents with idiopathic isolated growth hormone deficiency?
What adverse events are associated with discontinuing growth hormone therapy in mid-puberty and how are they managed?
What combination therapies or alternative approaches are being explored for idiopathic isolated growth hormone deficiency alongside Erasmus MC's research?